ResMed (RMD) vs Stryker (SYK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
ResMed (RMD) has outperformed Stryker (SYK) over the past year, losing 19.7% versus a loss of 26.2%. Over five years, SYK leads with a +4.0% price change compared with -11.3% for RMD. Stryker is the larger company by market cap ($106.99 billion vs $32.24 billion), about 3.3 times the size.
On valuation, Stryker trades at a lower forward P/E (16.7x vs 17.3x for ResMed). Stryker offers the higher dividend yield (1.25% vs 1.05%). ResMed converts more of its revenue into profit, with a net margin of 26.9% versus 12.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RMD | SYK |
|---|---|---|
| Share price | $229.22 | $278.93 |
| Market cap | $32.24B | $106.99B |
| 1-day change | +1.10% | +0.71% |
| YTD return | -5.87% | -21.20% |
| 1-year return | -19.70% | -26.20% |
| 5-year return | -11.26% | +4.00% |
| P/E ratio (TTM) | 21.98 | 28.91 |
| Forward P/E | 17.33 | 16.70 |
| EPS (TTM) | $10.43 | $9.65 |
| Dividend yield | 1.05% | 1.25% |
| Annual dividend | $2.40 | $3.48 |
| Revenue (latest FY) | $5.65B | $25.12B |
| Revenue growth (YoY) | +9.85% | +11.16% |
| Net income (latest FY) | $1.52B | $3.25B |
| Gross margin | 61.06% | 63.96% |
| Operating margin | 33.37% | 19.47% |
| Net margin | 26.94% | 12.92% |
| 52-week high | $277.85 | $392.55 |
| 52-week low | $180.27 | $267.00 |
| Distance from 52-week high | -17.50% | -28.94% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +9.16% | +31.27% |
| Average volume | 1.33M | 2.64M |
| Shares outstanding | 140.64M | 383.57M |
| Employees | 11,370 | 56,000 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Stryker is about 3.3 times larger than ResMed by market value ($106.99B vs $32.24B).
- Stryker trades at a higher earnings multiple (28.9x vs 22.0x trailing P/E).
- ResMed is more profitable, keeping 26.9 cents of every revenue dollar as net income versus 12.9 cents for Stryker.
About ResMed
RMD stock →ResMed Inc. engages in the digital health and cloud-connected medical devices business in the United States and internationally.
Health Care · Medical/Dental Instruments · 11,370 employees
About Stryker
SYK stock →Stryker Corporation operates as a medical technology company in the United States and internationally. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics.
Health Care · Medical/Dental Instruments · 56,000 employees
RMD vs SYK FAQ
Which is bigger, ResMed or Stryker?
Stryker (SYK) is larger, with a market capitalization of $106.99B compared with $32.24B for ResMed (RMD).
Which stock has performed better over the past year, RMD or SYK?
RMD returned -19.70% over the past 12 months, compared with -26.20% for SYK (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, RMD or SYK?
RMD has the lower trailing P/E at 22.0, versus 28.9 for SYK. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, ResMed or Stryker?
Stryker has the higher yield at 1.25%, compared with 1.05% for ResMed.
Are ResMed and Stryker in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.